Merz, V.; Cavaliere, A.; Messina, C.; Salati, M.; Zecchetto, C.; Casalino, S.; Milella, M.; Caffo, O.; Melisi, D.
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. Cancers 2020, 12, 1131.
https://doi.org/10.3390/cancers12051131
AMA Style
Merz V, Cavaliere A, Messina C, Salati M, Zecchetto C, Casalino S, Milella M, Caffo O, Melisi D.
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. Cancers. 2020; 12(5):1131.
https://doi.org/10.3390/cancers12051131
Chicago/Turabian Style
Merz, Valeria, Alessandro Cavaliere, Carlo Messina, Massimiliano Salati, Camilla Zecchetto, Simona Casalino, Michele Milella, Orazio Caffo, and Davide Melisi.
2020. "Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients" Cancers 12, no. 5: 1131.
https://doi.org/10.3390/cancers12051131
APA Style
Merz, V., Cavaliere, A., Messina, C., Salati, M., Zecchetto, C., Casalino, S., Milella, M., Caffo, O., & Melisi, D.
(2020). Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients. Cancers, 12(5), 1131.
https://doi.org/10.3390/cancers12051131